However, there was no significant difference in TNF-α between flunixin meglumine- and firocoxib-treated horses, and there were no significant differences in the development of SIRS, MODS, or clinical signs associated with either condition between groups [161]. This evidence concerns the gene TNF and systemic inflammatory response syndrome.